Multicenter, placebo-controlled trial of lorcaserin for weight management

The New England Journal of Medicine
Steven R SmithBehavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group

Abstract

Lorcaserin is a selective serotonin 2C receptor agonist that could be useful in reducing body weight. In this double-blind clinical trial, we randomly assigned 3182 obese or overweight adults (mean body-mass index [the weight in kilograms divided by the square of the height in meters] of 36.2) to receive lorcaserin at a dose of 10 mg, or placebo, twice daily for 52 weeks. All patients also underwent diet and exercise counseling. At week 52, patients in the placebo group continued to receive placebo but patients in the lorcaserin group were randomly reassigned to receive either placebo or lorcaserin. Primary outcomes were weight loss at 1 year and maintenance of weight loss at 2 years. Serial echocardiography was used to identify patients in whom valvulopathy (as defined by the Food and Drug Administration) developed. At 1 year, 55.4% of patients (883 of 1595) receiving lorcaserin and 45.1% of patients (716 of 1587) receiving placebo remained in the trial; 1553 patients continued into year 2. At 1 year, 47.5% of patients in the lorcaserin group and 20.3% in the placebo group had lost 5% or more of their body weight (P<0.001), corresponding to an average loss of 5.8+/-0.2 kg with lorcaserin and 2.2+/-0.1 kg with placebo during ye...Continue Reading

References

Aug 28, 1997·The New England Journal of Medicine·H M ConnollyH V Schaff
Jun 1, 2000·Obesity Research·I L Mertens, L F Van Gaal
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Apr 18, 2002·European Journal of Clinical Nutrition·H H DitschuneitM Flechtner-Mors
Jul 27, 2002·Science·Lora K HeislerJoel K Elmquist
Aug 7, 2002·Pharmacology & Therapeutics·Richard B Rothman, Michael H Baumann
Sep 17, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·R PadwalD C W Lau
Feb 16, 2006·JAMA : the Journal of the American Medical Association·F Xavier Pi-SunyerUNKNOWN RIO-North America Study Group
Nov 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Patricia R CaseyUNKNOWN ODIN Group
Jan 5, 2007·The New England Journal of Medicine·Bryan L Roth
Jan 5, 2007·The New England Journal of Medicine·René SchadeEdeltraut Garbe
Jan 5, 2007·The New England Journal of Medicine·Renzo ZanettiniGianni Pezzoli
Mar 14, 2007·Archives of Neurology·Richard B DeweyPadraig E O'Suilleabhain
Aug 21, 2007·Lancet Neurology·Angelo Antonini, Werner Poewe
Feb 7, 2008·The Journal of Pharmacology and Experimental Therapeutics·William J ThomsenDominic Behan
Dec 6, 2008·Obesity·Steven R SmithUNKNOWN APD356-004 Study Group
Apr 25, 2009·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·A N FabricatoreA M Nguyen

❮ Previous
Next ❯

Citations

Nov 14, 2012·Archives of Internal Medicine·Kishore M GaddeGeorge A Bray
Nov 25, 2011·Current Atherosclerosis Reports·Leon I IgelLouis J Aronne
Apr 30, 2013·Current Hypertension Reports·Donna H Ryan, George A Bray
Aug 13, 2013·Current Hypertension Reports·Stefan Engeli, Jens Jordan
May 17, 2013·Endocrine·Guido Di DalmaziUberto Pagotto
Apr 13, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Srividya Kidambi, Theodore A Kotchen
Jul 16, 2013·Neuropharmacology·Kathryn A Cunningham, Noelle C Anastasio
Nov 4, 2011·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Graziela Z Kalil, William G Haynes
Aug 30, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·R Sherafat-KazemzadehJ A Yanovski
Mar 14, 2012·International Journal of Obesity : Journal of the International Association for the Study of Obesity·D J HealS L Smith
Aug 16, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·T A WaddenUNKNOWN POWER-UP Research Group
Jul 1, 2012·International Journal of Obesity Supplements·N Gesundheit
Oct 12, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sophie M BanasLuc Maroteaux
Dec 23, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Guy A HigginsPaul J Fletcher
Aug 4, 2012·Nature Reviews. Drug Discovery·Marcelo O Dietrich, Tamas L Horvath
Jun 12, 2013·Nature Reviews. Endocrinology·Christian F Rueda-ClausenArya M Sharma
Jul 22, 2010·The New England Journal of Medicine·Arne Astrup
Dec 30, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C Sessa
Apr 23, 2013·JAAPA : Official Journal of the American Academy of Physician Assistants·Melissa Murfin
Dec 7, 2013·Cardiology in Review·Grace Shyh, Angela Cheng-Lai
Sep 23, 2010·The Journal of Pharmacology and Experimental Therapeutics·W E FantegrossiJ H Woods
Jun 4, 2011·The Journal of Pharmacology and Experimental Therapeutics·Edward D LevinJed E Rose
Dec 3, 2013·The Journal of Clinical Investigation·Herbert Y Meltzer, Bryan L Roth
Mar 22, 2013·Health Economics Review·Kenneth E ThorpeW Timothy Garvey
Dec 31, 2010·The Journal of Clinical Endocrinology and Metabolism·Corby K MartinEric Ravussin
May 19, 2011·Drugs of Today·L M Redman, E Ravussin
Jun 7, 2013·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Barbora DoslikovaLora K Heisler
Mar 31, 2011·Drug Design, Development and Therapy·Nicholas T Bello, Nu-Chu Liang
Jan 27, 2011·Drug Design, Development and Therapy·Bo Bai, Yu Wang
Jan 1, 2011·Pharmacogenomics and Personalized Medicine·Tessa Jm WallaceDaniel J Müller
Jun 2, 2012·Therapeutics and Clinical Risk Management·Susan L McElroyAnne M O'Melia
Nov 17, 2011·Drugs·Jason C G HalfordJoanne A Harrold
Feb 2, 2012·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Marietta Charakida, Nicholas Finer
Mar 25, 2011·Future Medicinal Chemistry·Jean-Philippe Chaput, Angelo Tremblay
Oct 30, 2012·Clinical Medicine : Journal of the Royal College of Physicians of London·Rebeca CarterJude Oben
May 7, 2014·Journal of Pharmacology & Pharmacotherapeutics·Dick B S BrashierAnjan Khadka
Jan 19, 2013·Pharmacogenomics·Adrián LlerenaHumberto Fariñas
Nov 12, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A D Miras, C W le Roux
Jun 19, 2013·International Journal of Obesity : Journal of the International Association for the Study of Obesity·L FaniE L T van den Akker
Dec 24, 2013·Journal of Pharmacological and Toxicological Methods·Icilio Cavero, Jean-Michel Guillon
May 21, 2014·Nature Reviews. Neuroscience·Gregory J MortonMichael W Schwartz
Jun 6, 2014·International Journal of Endocrinology·J Michael Gonzalez-CampoyMiguel Gonzalez Ahumada
Apr 8, 2014·The Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists·Daniel A Hussar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.